Trial Profile
A Phase I, Multi-center, Open-label, Single Dose Study, to Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients With or Without Renal Impairment.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Dec 2010
Price :
$35
*
At a glance
- Drugs AZD 1656 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- 08 Dec 2010 Actual initiation date (Mar 2010) added as reported by ClinicalTrials.gov.
- 07 Dec 2010 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
- 26 Aug 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.